sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its opening position concerning Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover Panel Act, 1997. The disclosure indicates Vanguard's interests in Avadel's ordinary shares as of February 5, 2026.
Vanguard holds 5,799,501 US$0.01 ordinary shares, representing 5.95% of Avadel's relevant securities. Recent transactions by Vanguard include the purchase of 9,211 shares and the sale of 96 shares, both priced at 21.60 USD per share.
No cash-settled or stock-settled derivatives, such as options or agreements to purchase or sell, were disclosed. Furthermore, Vanguard reported no indemnity or option arrangements related to Avadel's securities, nor any agreements regarding voting rights or future acquisitions or disposals of these securities.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.